ロード中...
Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection
BACKGROUND: HCV direct-acting antivirals (DAAs) are produced in India at low cost. However, concerns surrounding reinfection and budgetary impact limit treatment scale-up in India. We evaluate the cost-effectiveness and budgetary impact of HCV treatment in India, including reinfection. METHODS: A cl...
保存先:
| 出版年: | PLoS One |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Public Library of Science
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6553784/ https://ncbi.nlm.nih.gov/pubmed/31170246 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0217964 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|